Abstract
Objective To investigate the association of genetically proxied Phosphodiesterase 5 (PDE5) inhibition with fertility, sexual activity, and subjective wellbeing in men.
Design Two-sample cis-Mendelian randomisation.
Setting Genetic association data obtained from the International Consortium for Blood Pressure (ICBP) and UK Biobank (UKB).
Participants European ancestry individuals from the ICBP (N = 757,601) and the UKB (N ≈ 450,000). Genetic association data were leveraged from the ICBP for the exposure and from the UKB for the outcomes.
Intervention Genetically proxied PDE5 inhibition, scaled to the effect of 100mg daily sildenafil on diastolic blood pressure.
Main outcome measures Number of children, age of first having sex, number of sexual partners, odds of being a virgin and self-reported wellbeing, all measured in the male sub-sample of the UKB.
Secondary outcomes To explore the specificity of our results, we replicate our analysis in the female sub-sample of the UKB. We additionally explored possible confounders/mediators of our instruments using PhenoScanner, and adjust for them using Two-step cis-MR.
Results Genetically proxied sildenafil was associated with fathering 0.21 (95% CI: 0.08– 0.35) more children (FDR corrected p = 0.01). This association was neither attenuated when adjusting for traits associated with our instruments nor was it replicated in women. We did not find robust evidence for an effect of sildenafil on the age of first having sex, number of sexual partners, odds of being a virgin, or self-reported wellbeing.
Conclusions This study provides genetic support for PDE5 inhibitors increasing the number of children that men have.
Key Messages
- Sildenafil is a PDE5 inhibitor that is commonly used in the treatment of erectile dysfunction and pulmonary hypertension.
- Drug-target Mendelian randomisation is a quasi-experimental method that uses genetic variants to proxy drug-target perturbation. Here, we leverage this approach to investigate long-term therapeutic and adverse effects of sildenafil use, many of which cannot be easily evaluated in a randomised controlled trial.
- We find evidence for a casual association between genetically proxied sildenafil use and number of children fathered. Genetically proxied sildenafil use was not associated with age at first having sex, number of sexual partners, odds of being a virgin, or subjective wellbeing.
Competing Interest Statement
DG is employed part-time by Novo Nordisk. The authors declare no conflicts of interest.
Funding Statement
BW is funded by an Economic and Social Research Council (ESRC) South West Doctoral Training Partnership (SWDTP) 1+3 PhD Studentship Award (ES/P000630/1). SB is supported by the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7) and the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. DG is supported by the British Heart Foundation Centre of Research Excellence at Imperial College London (RE/18/4/34215).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UKB received ethics approval from the North West Multi-Centre Research Ethics Committee (REC reference 11/NW/0382). All participants provided written informed consent to participate in the study. Data from the UKB are fully anonymised.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that was used in this study is publicly available from the MRC-IEU OpenGWAS platform. The R code used in the manuscript, and GWASs created for this project, are available from https://doi.org/10.17605/OSF.IO/MUERZ.
